ALK and non-small cell lung carcinoma: Consistent with these biological mechanisms, a correlation between oncogene mutations and the frequency of thrombosis has recently been reported in various malignancies, including KRAS mutation in NSCLC and colorectal cancer [64,65], ALK receptor tyrosine kinase (ALK) rearrangement in NSCLC [66,67,68], and ROS proto-oncogene 1 (ROS1) rearrangement in NSCLC [68,69] are at high risk for CAT.